Experts are working on novel immune-enhancing therapies called host-directed therapies to use the body's own immune system to target tuberculosis, with hopes that they could tackle even the drug-resistant forms of the disease. ...
Apr 26, 2024
0
0
People who take acid-reducing drugs may have a higher risk of migraine and other severe headache than people who do not take these medications, according to a study published in the April 24, 2024, online issue of Neurology ...
Apr 24, 2024
0
2
University of Hawaiʻi Cancer Center researchers have conducted a phase II clinical trial investigating the potential of pembrolizumab maintenance therapy, a type of immunotherapy, in aggressive forms of breast cancer. The ...
Apr 18, 2024
0
9
Keeping blood pressure under control could be crucial for women in preventing uterine fibroids, new research shows.
Apr 16, 2024
0
0
Patient prognosis and treatment response prediction are key factors in treating ovarian cancer, which is characterized by the lowest survival rate among gynecological cancers. Consequently, there is strong demand for a more ...
Apr 15, 2024
0
0
More than 75% of the patients treated at the psychiatric outpatient clinic of Hospital de Base in São José do Rio Preto, São Paulo state (Brazil), are women with a mean age of 45 and suffering from sadness, anxiety, and ...
Apr 11, 2024
0
21
TG4050, a personalized neoantigen vaccine, induced tumor-specific immune responses and led to low rates of disease relapse in patients with surgically resected HPV-negative head and neck squamous cell cancer (HNSCC), according ...
Apr 9, 2024
0
14
AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, demonstrated a manageable safety profile in both recurrent and newly diagnosed glioblastoma (GBM) patients when given in combination with standard-of-care radiotherapy ...
Apr 9, 2024
0
1
Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment with high-dose anthracycline chemotherapy did not show any difference in troponin T levels, a biomarker associated with ...
Apr 8, 2024
0
0
The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free survival and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal ...
Apr 8, 2024
0
0
